Drug Profile

Research programme: protein nanoparticles based CNS targeting therapeutics - Aera Therapeutics

Latest Information Update: 26 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Nov 2025 Early research in CNS disorders in USA (Parenteral) (Prior to November 2025) (Aera Therapeutics pipeline, November 2025)
04 Nov 2024 Aera Therapeutics has the patent pending for "Capsids with effector-polypeptide conjugates and uses thereof" (WO 202 509 713 2A1) worldwide
01 Feb 2024 Aera Therapeutics has patent protection for "Endogenous gag-based and pnma family capsids and uses thereof" (WO 202 402 629 5A1) worldwide

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com